Subcutaneous beloranib: Additional Phase III data

Additional data from the double-blind, U.S. Phase III bestPWS (ZAF-311) trial in 107 patients with Prader-Willi syndrome showed that twice-weekly 1.8 and 2.4 mg doses of subcutaneous beloranib each met the secondary endpoints of reducing from baseline to week 26 mean LDL-C (16.6

Read the full 436 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE